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Abstract
Background: The use of artificial nutrition, defined as a medical treatment that al-
lows a non-oral mechanical feeding, for cancer patients with limited life expectancy 
is deemed nonbeneficial. High-quality evidence about the use of artificial nutrition 
near the end of life is lacking. This study aimed (a) to quantify the use of artificial 
nutrition near the end-of-life, and (b) to identify the factors associated with the use 
of artificial nutrition.
Methods: This was a retrospective cohort study of decedents based on data from 
the French national hospital database. The study population included adult cancer 
patients who died in hospitals in France between 2013 and 2016 and defined to be in 
a palliative condition. Use of artificial nutrition during the last 7 days before death 
was the primary endpoint.
Results: A total of 398 822 patients were included. The median duration of the last 
hospital stay was 10 (interquartile range, 4-21) days. The artificial nutrition was used 
for 11 723 (2.9%) during the last 7 days before death. Being a man, younger, having 
digestive cancers, metastasis, comorbidities, malnutrition, absence of dementia, and 
palliative care use were the main factors associated to the use of artificial nutrition.
Conclusion: This study indicates that the use of artificial nutrition near the end of 
life is in keeping with current clinical guidelines. The identification of factors as-
sociated with the use of artificial nutrition, such as cancer localization, presence of 
comorbidities or specific symptoms, may help to better manage its use.
K E Y W O R D S
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1 |  INTRODUCTION
During the last decades, the care management of advanced 
cancer patients near the end of life has prioritized symptom 
management, psychological support, and advanced care plan-
ning to preserve quality of life. Cancer care in the context 
of limited life expectancy is a challenge (clinically and eth-
ically) that physicians have to face in their daily practice.1
Several factors have been shown to have no or negative ef-
fects on patients' outcomes during this specific time. The use 
and/or continuation of aggressive care (in particular chemo-
therapy) close to death is widely deemed nonbeneficial due 
to a limited effect on overall survival, symptom deterioration, 
and the high burden of toxicity, leading to impairments (or 
the absence of improvement) in quality of life.2-5 The early 
integration of palliative care into standard oncological care 
seems to be associated with improved patient outcomes in the 
last days before death.6,7 However, the question of whether to 
maintain artificial nutrition, defined as a medical treatment 
that allows a non-oral mechanical feeding either by intrave-
nous or enteral route for a person no longer able to take nutri-
tion by mouth, is still discussed.
While artificial nutrition is a key component of care for 
cancer patients in general (eg, prevention of weight loss and 
malnutrition, prevention of side-effects from anticancer treat-
ments),8,9 its use for patients with a shortened life expectancy 
appears nonbeneficial.10,11 In fact, the implementation of ar-
tificial nutrition in the terminal and dying phase may be con-
sidered a health risk (eg, infectious, respiratory, metabolic 
disorders12), may result in the discomfort of the patient, and 
may be a source of health costs.
Few studies have reported robust information about the 
use of artificial nutrition for patients with limited life ex-
pectancy. Based on a 2011 review, the frequency of use of 
artificial nutrition in the last week of life varied between 
studies, from 3% to 50%.13 A recent French study, focusing 
on patients with metastatic oesophageal/stomach cancer who 
died between 2010 and 2013, reported that more than 15% 
of the patients received artificial nutrition in the last week 
of life,14 while the French Society of Clinical Nutrition and 
Metabolism recommends artificial nutrition only in patients 
with an expected life-expectancy greater than 3 months (https 
://sfncm.org/image s/stori es/Reco_oncol ogie_final.pdf; last 
visit 2018, December). We may hypothesize that patients 
receiving artificial nutrition differ from other patients in 
terms of the presence of specific symptoms or malnutrition 
or needs in the last days of life. A better understanding of the 
factors associated with the use of artificial nutrition may help 
clinicians better manage its use and may improve communi-
cation with patients, families, and health policy makers. We 
provide, for the first time, robust information about the use of 
artificial nutrition during the last days before death from the 
French national hospital database.
The aims of this study were (a) to quantify the use of ar-
tificial nutrition near the end-of-life (during the 7 and 31 last 
days of life15) for hospitalized cancer patients, and (b) to iden-
tify the factors associated with the use of artificial nutrition.
2 |  METHOD
2.1 | Design
This was a French population-level retrospective cohort 
study based on data extracted from the French national hos-
pital database (Programme de Médicalisation des Systèmes 
d'Information) including administrative and medical in-
formation collected in both public and private hospitals in 
France. Diagnoses are coded according to the International 
Classification of Diseases, Tenth Revision (ICD-10).
2.2 | Population
The study population included all cancer patients aged 
17 years and older who died during a hospital stay between 
1 January 2013 and 31 December 2016. Patients were identi-
fied using the algorithm developed by the French National 
Cancer Institute (French, Institut National du Cancer 
[INCa]), the algorithm was specifically designed to identify 
cancer-related treatments with routinely collected data (INCa 
2013). Patients were included if they were in a palliative care 
situation according to the definition used in previous works 
involving the French national hospital database16: diagnosed 
with cancer at a metastatic stage, brain cancer, or liver can-
cer (regardless of the stage of the disease as these tumors 
are rarely metastatic and are usually lethal at locoregional 
stages). Patient care managed in rehabilitation centers and at 
home could not be included given the nature of the registry. 
The access to this national database is granted according to 
the French law and is available for accredited provider.
2.3 | Outcomes
Two main outcomes were studied: the use of artificial nu-
trition during: (a) the last 7  days before death (primary 
outcome) and (b) the last 31 days before death (secondary 
outcome). The rationale for the last 7 and 31  days before 
death was based on the Earle's work.15
The use of artificial nutrition was defined as the pres-
ence of enteral or parenteral nutrition related to acute care 
during a hospitalization stay, using the French classification 
of medical acts (https ://www.ameli.fr/accue il-de-la-ccam/
index.php) (codes are provided in the Appendix). Enteral nu-
trition includes nutrition provided through either nasogastric 
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tubes or gastrostomy, esophogostomy, or jejunostomy tubes. 
Parenteral nutrition includes nutrition administered through 
a peripheral vein or a central line called total parenteral 
nutrition.
2.4 | Factors associated with 
artificial nutrition
The following data were extracted:
• Sociodemographic information: age, gender, and year of 
death;
• Characteristics of the last hospitalization stay before death: 
duration and type of hospital (specialized or nonspecial-
ized hospital);
• General clinical information: cancer localization, chronic 
comorbid condition based on the modified Charlson co-
morbidity index17 (score computed as the number of co-
morbidities excluding cancer-related items), presence 
and severity of malnutrition (five classes: absence, mild, 
moderate, severe, and undefined severity), presence of a 
biological/clinical situation that is potentially source a rea-
son for the implementation/maintenance of artificial nutri-
tion (eight items: cachexia, anorexia, metabolic disorders 
(dysnatremia, dyskalemia, others), mucositis/stomatitis, 
hepatic disorders (acute and chronic hepatitis, hepatic fail-
ures…), digestive symptoms, respiratory symptoms, skin 
ulcerations), and dementia. All the codes and labels are 
detailed in the Appendix. The rationale for selecting the 
specific factors was based on biological or clinical situa-
tions potentially source of prescription or non-prescription 
of artificial nutrition.
• Care management during the last 7 and 31 days before death: 
chemotherapy use and palliative care use (Appendix).
2.5 | Statistical analysis
Descriptive analyses of socio-demographic information, hos-
pital stay, general clinical information, and care management 
were presented as frequencies and percentages. The percent-
ages of patients who received artificial nutrition in the last 
7 and 31 days before death were calculated. Each outcome 
was used as a separate dependent variable. Univariate as-
sociations between sociodemographic information, hospi-
tal stay, general clinical information, and care management 
and each outcome were performed using univariate logistic 
regression. Variables relevant to the model were selected 
based on a threshold P-value (≤.05) in the univariate analy-
sis and included in a multivariate logistic model to predict 
the odds of receiving artificial nutrition in the last 7 and 
31 days before death. Adjusted odds ratios (ORs) with 95% 
confidence intervals (95% CIs) were calculated. Statistical 
significance was defined as P < .05. The statistical analysis 
was performed in accordance with the REporting of studies 
Conducted using Observational Routinely-collected health 
Data statement. The statistical analysis was performed with 
SAS 9.4 (SAS Institute) and the logistic regression used the 
PROC LOGISTIC model in SAS.
3 |  RESULTS
3.1 | Population
A total of 398 822 hospitalized cancer patients who died be-
tween 1 January 2013 and 31 December 2016 met the inclu-
sion criteria. A flow diagram detailing the selection of cases 
is shown in Figure 1. The median duration of the last hos-
pitalization was 10  days (interquartile range 4-21) and the 
duration was less than 7 days in almost 40% of the patients. 
The patients were predominantly men (59%), and 30% of 
them were aged over 80 years at the time of death. Digestive 
cancers (34%), including pancreatic (7%) and oesophageal 
(6%) cancers, and lung cancer (24%) were the most frequent 
cancers among the patients. Sixty percent of the patients 
presented at least one chronic comorbidity according to the 
modified Charlson index. One-fifth of the patients received 
chemotherapy in the last 31 days before deaths vs 8% in the 
last 7 days before death. One quarter of the patients were not 
labeled as receiving palliative care. All the details are shown 
in Table 1. The use of artificial nutrition during the last 7 days 
and the last 31 days before death was found in 11 723 (2.9%) 
patients and 20 429 (5.1%) patients, respectively.
3.2 | Factors associated with artificial 
nutrition during the last 7 days before death
Artificial nutrition was more often received by men, younger 
individuals, and patients with longer hospitalization dura-
tions. The presence of higher number of comorbidities, pres-
ence of malnutrition, and the following clinical/biological 
items were more often associated with the use of artificial 
nutrition: cachexia, metabolic disorders, mucositis/stomati-
tis, hepatic disorders, digestive symptoms, respiratory symp-
toms, and skin ulceration. Artificial nutrition was used more 
often for digestive and head-and-neck localizations than 
for other cancers. The presence of metastasis and dementia 
were less often associated with the use of artificial nutri-
tion. Chemotherapy use during the last 7 days before death 
was more often associated with the use of artificial nutrition, 
while the use of palliative care was less often associated with 
the use of artificial nutrition. The use of artificial nutrition 
was slightly less frequent in 2015. The multivariate models 
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confirmed these findings, except for the findings regarding 
chemotherapy use. The univariate analysis results are de-
tailed in Table 2 and the multivariate analysis results are de-
tailed in Table 3.
3.3 | Factors associated with artificial 
nutrition during the last 31 days before death
The factors associated with artificial nutrition during the last 
31 days before death were the same factors that were asso-
ciated with artificial nutrition during the last 7 days before 
death except for anorexia which was only associated with 
artificial nutrition during the last 31 days before death. The 
univariate analysis results are detailed in Table 2 and the 
multivariate analysis results are detailed in Table 3.
4 |  DISCUSSION
The first important finding of this study was the relatively 
low proportion of use of artificial nutrition during the last 
days before death in French cancer patients with a limited 
expected life-expectancy: the proportion was 5% in the last 
month of life and less than 3% in the last 7 days of life. While 
the French national context is characterized by a high level of 
medicalization in the last months and weeks of life compared 
with that of other European countries,18 this result indicates 
that the artificial nutrition management for patients with ad-
vanced illness was in accordance with the available clinical 
guidelines,10,11 even though the recommendation was based 
on sparse evidence-based medicine findings. Previous stud-
ies most often reported higher proportions. For example, four 
studies19-22 included in the 2011 review13 reported frequen-
cies of artificial nutrition in the last week of life from 3% 
to 50%. However, these four studies were all performed in 
Asian countries and it is well-documented that the frequen-
cies of artificial nutrition use may be influenced by cultural/
legal differences in end-of-life decision making.23 Another 
study,14 which used a similar population-based study design 
as ours and that was performed on French cancer patients, 
showed that more than 15% of patients benefited of artificial 
nutrition during the last month before death, with a slight in-
crease in the last week of life. However, this study reported 
data from an earlier period (from 2010 to 2013), included 
patients cared for in rehabilitation units, and focused on pa-
tients with advanced upper digestive tract cancers, known to 
be cancers for which artificial nutrition remains a key com-
ponent of care.24 Artificial nutrition can also induce bron-
chorrhea, which is a cause of discomfort. This new data has 
probably reduced the number of prescriptions for artificial 
nutrition.25
The second interesting finding of the study is the fac-
tors that were associated with the use of artificial nutrition 
F I G U R E  1  Flow diagram
Cancer patients who died during 
a conventional hospitalization 
stay between 2013 and 2016
N = 489 388
Cancer patients >= 17 y who  
died during a conventional 
hospitalization stay between 
2013 and 2016
N = 487 951
Population
N = 398 822
Exclusion of 
patients with a cancer at a 
metastatic stage, a brain 
cancer, or a liver cancer   
Exclusion of 
patients <16 y
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during the last days of life. Women and, more interestingly, 
the oldest patients were those who benefited least from ar-
tificial nutrition: these two findings were found in previous 
similar reports.14 While we hypothesized that artificial nutri-
tion would most often be used for patients in care-managed in 
nonspecialty centers compared to specialty centers (including 
university hospital and cancer centers), we found the opposite 
result. It should be expected that the professional caregivers 
working in specialty centers use less artificial nutrition.13,22 
Indeed, previous studies reported that professional caregiv-
ers working in specialty centers were more concerned about 
the burden of artificial nutrition in the last weeks of life (and 
were more reserved about the benefits in terms of the allevi-
ation of symptoms).20,26 However, the study by Kempf et al, 
which used a similar design as was used in our study, showed 
a comparable result.14 One partial explanation may be the de-
ficiency of robust predictive factors of dying. Future research 
should provide tools or scores to improve this prediction in 
the last days of life to better manage the end-of-life period. 
Unsurprisingly, the use of artificial nutrition was more fre-
quent in patients with digestive and head-and-neck cancers 
compared to its use in patients with other localizations. At 
of the end of life, artificial nutrition is often a key compo-
nent of cancer care for these specific cancers.27 In addition, 
while the use of artificial nutrition is not recommended in 
patient with short life-expectancy, the decision to stop or 
withdraw artificial nutrition may be even harder for both the 
medical staff and the family. In accordance with the guide-
lines, the presence of metastasis and increased comorbidities 
should theoretically be associated with less use of artificial 
nutrition. This is the case for patients with metastasis, but 
an increasing number of comorbidities have been associated 
with a higher use of artificial nutrition. Indeed, patients with 
comorbidities probably present with a more deteriorated gen-
eral health status, than patients without comorbidities, which 
should lead to a decision to stop artificial nutrition. The lit-
erature provides discordant results about this association: an 
T A B L E  1  Characteristics N = 398 822
  N (%)
Sex
Women 162 506 (40.8)
Men 236 316 (59.3)
Age at death (years)
<60 77 469 (19.4)
[60;70] 102 760 (25.8)
[70;80] 101 295 (25.4)
≥80 117 298 (29.4)
Year of death
2013 96 868 (24.3)
2014 98 948 (24.8)
2015 100 383 (25.2)
2016 102 623 (25.7)
Last hospitalization stay duration
≥7 d 242 071 (60.7)
≥31 d 47 952 (12.0)
Hospital type
Non specializeda 300 347 (75.3)
Specializeda 98 475 (24.7)
Cancer localization
Digestive 134 934 (33.8)
Pancreas 29 660 (7.4)
Esophageal 23 340 (5.9)
Others 81 934 (20.5)
Lung/thoracic 95 068 (23.8)
Genital (male and female) 44 368 (11.1)
Breast 34 193 (8.6)
Hematologic 32 320 (8.1)
Urinary tract 29 099 (7.3)
Head and neck 18 635 (4.7)
Nervous system 11 960 (3.0)
Othersb 17 289 (4.3)
Unknown primary site 8170 (2.1)
Comorbidities (Charlson)c
0 160 316 (40.2)
1 or 2 141 498 (35.5)
3 or 4 64 112 (16.1)
≥5 32 896 (8.3)
Diabete without complication 72 634 (18.2)
Congestive heart failure 67 122 (16.8)
Chronic pulm. disease 54 515 (13.7)
Renal disease 44 671 (11.2)
Malnutrition
The last 7 d 119 296 (29.9)
(Continues)
  N (%)
The last 31 d 147 775 (37.1)
Chemotherapy use
The last 7 d 31 926 (8.0)
The last 31 d 85 580 (21.5)
Palliative care use
The last 7 d 297 012 (74.5)
The last 31 d 301 424 (75.6)
aSpecialized centers include cancer units of an university hospital and units of a 
cancer hospital, non-specialized centers include all the other cases. 
bOthers: skin (2.52%), bone (1.10%), endocrine glands (0.58%), eye (0.14%). 
cCharlson modified score (excluding malignancies/metastasis). 
T A B L E  1  (Continued)
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T A B L E  2  Factors associated to artificial nutrition use in the last 7 and 31 d before death (univariate analysis)
 
The last 7 d before death The last 31 d before death
N = 11 723 (2.9%)
OR (95% CI) P
N = 20 429 (5.1%)
OR (95% CI) PN (%) N (%)
Sex
Women (ref) 3932 (2.4)     7252 (4.5)    
Men 7591 (3.2) 1.34 (1.29-1.39) <.001 13 177 (5.6) 1.26 (1.23-1.3) <.001
Age at death (years)
<60 (ref) 2904 (3.8)     5223 (6.7)    
[60;70] 3691 (3.6) 0.96 (0.91-1.01) .079 6495 (6.3) 0.93 (0.90-0.97) <.001
[70;80] 3153 (3.1) 0.82 (0.78-0.87) <.001 5486 (5.4) 0.79 (0.76-0.82) <.001
≥80 1775 (1.5) 0.39 (0.37-0.42) <.001 3225 (2.8) 0.39 (0.37-0.41) <.001
Year of death
2013 (ref) 2869 (3.0)     5019 (5.2)    
2014 2908 (2.9) 0.99 (0.94-1.05) .77 5216 (5.3) 1.02 (0.98-1.06) .370
2015 2744 (2.7) 0.92 (0.87-0.97) .002 4977 (5.0) 0.95 (0.92-0.99) .024
2016 3002 (2.9) 0.99 (0.94-1.04) .630 5217 (5.1) 0.98 (0.94-1.02) .323
Hospitalization stay duration (days)
≤7 (ref) 3895 (2.5)     5924 (3.8)    
[8-31] 6002 (3.1) 1.25 (1.2-1.3) <.001 11 492 (5.9) 1.60 (1.55-1.65) <.001
>31 1626 (3.4) 1.38 (1.3-1.46) <.001 3013 (6.3) 1.71 (1.63-1.79) <.001
Hospital type
Non speciality 7330 (2.4)     13 334 (4.4)    
Speciality 4193 (4.3) 1.78 (1.71-1.85)   7095 (7.2) 1.67 (1.62-1.72) <.001
Cancer localization
NDHANa (ref) 6251 (2.5)     10 587 (4.2)    
Digestiveb 4230 (3.2) 1.31 (1.26-1.36) <.001 7735 (5.9) 1.43 (1.39-1.47) <.001
Head and neck 1042 (6.2) 2.57 (2.4-2.75) <.001 2107 (12.5) 3.23 (3.08-3.40) <.001
Metastasis
(ref: no) 7044 (2.8) 0.87 (0.84-0.9) <.001 12 658 (4.9) 0.90 (0.87-0.93) <.001
Comorbidities (Charlson)c
Absence (ref) 3930 (2.5)     7341 (4.6)    
1 or 2 4363 (3.1) 1.27 (1.21-1.32) <.001 7585 (5.4) 1.18 (1.14-1.22) <.001
3 or 4 2035 (3.2) 1.3 (1.24-1.38) <.001 3474 (5.4) 1.19 (1.15-1.24) <.001
≥5 1195 (3.6) 1.5 (1.4-1.6) <.001 2029 (6.2) 1.37 (1.3-1.44) <.001
Malnutrition
Absence (ref) 6572 (2.4)     9072 (3.6)    
Mild 268 (6.1) 2.68 (2.36-3.04) <.001 533 (9.2) 2.71 (2.47-2.97) <.001
Moderate 1343 (3.9) 1.69 (1.60-1.80) <.001 2930 (6.7) 1.93 (1.84-2.01) <.001
Severe 3037 (4.1) 1.79 (1.71-1.87) <.001 7294 (8.1) 2.35 (2.28-2.42) <.001
Other casesd 303 (4.3) 1.85 (1.65-2.08) <.001 600 (7.2) 2.06 (1.89-2.25) <.001
Presence of specific situation(s)e,f
No (ref) 3070 (2.1)     3722 (3.3)    
At least oneg 8453 (3.4) 1.66 (1.59-1.73) <.001 16 707 (5.9) 1.86 (1.79-1.93) <.001
Cachexia            
(Continues)
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increasing number of comorbidities may be associated with a 
lower16 or a higher14 use of artificial nutrition. Malnutrition 
and the presence of medical (biological-clinical) situations, 
which are potential indications for artificial nutrition, were 
all more frequently associated with the presence of artificial 
nutrition as a compensation for an alteration of general health 
status. However, for some items, it is well-known that artifi-
cial nutrition was not effective.11 Bronchial congestion (as a 
consequence of lower albuminemia due to hypercatabolism) 
and nausea/vomiting/diarrhea can be worsened by enteral 
nutrition. Malnutrition, cachexia, and metabolic disorders, 
as a consequence of inflammatory phenomena, are gener-
ally not improved by artificial nutrition. Despite the growing 
evidence against artificial nutrition use among patients with 
advanced dementia, little is known about the perspectives of 
the healthcare team.28 In this large population, we can say 
that healthcare providers were widely in accordance with the 
current evidence-based knowledge about artificial nutrition 
for patients with dementia at the end of life. One important 
finding was the association found between a less use of artifi-
cial nutrition for patients labeled as being in “palliative care.” 
In a care model in which the palliative approach is fully inte-
grated into the standard practice, the withdrawal of artificial 
nutrition is more likely to be understood by cancer patients 
and their relatives. The role of palliative care specialists is not 
only to provide care to patients with complex clinical needs 
but also to assist medical teams with ethically challenging 
decision making.29
 
The last 7 d before death The last 31 d before death
N = 11 723 (2.9%)
OR (95% CI) P
N = 20 429 (5.1%)
OR (95% CI) PN (%) N (%)
(ref: no) 628 (3.3) 1.14 (1.05-1.23) .002 1451 (6.6) 1.33 (1.26-1.41) <.001
Anorexia            
(ref: no) 673 (2.8) 0.95 (0.88-1.02) .175 1807 (5.7) 1.12 (1.07-1.18) <.001
Metabolic disorders            
(ref: no) 4578 (4.5) 1.99 (1.92-2.07) <.001 9121 (0.07) 1.86 (1.81-1.91) <.001
Mucositis/stomatitis            
(ref: no) 617 (3.3) 1.16 (1.06-1.26) <.001 1591 (6.8) 1.39 (1.32-1.46) <.001
Hepatic disorders            
(ref: no) 1575 (4.3) 1.58 (1.49-1.66) <.001 2689 (6.6) 1.35 (1.29-1.41) <.001
Digestive symptoms            
(ref: no) 2711 (3.5) 1.28 (1.22-1.33) <.001 6529 (6.8) 1.51 (1.46-1.55) <.001
Respiratory symptoms            
(ref: no) 1604 (3.5) 1.26 (1.2-1.33) <.001 3459 (6.3) 1.3 (1.25-1.35) <.001
Skin ulceration            
(ref: no) 1732 (3.2) 1.12 (1.06-1.18) <.001 3771 (6.2) 1.28 (1.23-1.32) <.001
Dementia            
(ref: no) 208 (1.5) 0.5 (0.44-0.58) <.001 446 (2.8) 0.52 (0.47-0.57) <.001
Chemotherapy usef            
(ref: no) 1236 (3.9) 1.4 (1.31-1.48) <.001 5406 (6.3) 1.34 (1.3-1.38) <.001
Palliative care usef            
(ref: no) 6492 (2.2) 0.43 (0.41-0.45) <.001 13 563 (4.5) 0.62 (0.6-0.64) <.001
Note: Bold values: P-values < .05.
Abbreviations: OR (95% CI), odd ratio with the 95% confidence interval; Ref, modality of reference.
aNDHAN: Non-digestive and non-head-and-neck cancers. 
bDigestive cancers: oesophageal, pancreas, and other digestive localizations. 
cCharlson modified score (excluding malignancies/metastasis). 
dProtein energy malnutrition non-defined according to severity. 
eBiological and/or clinical situations potentially source of prescription of artificial nutrition. 
fThe last 7 or 31 d depending on the endpoint (last 7 or 31 d before death, respectively). 
gCachexia and/or anorexia and/or metabolic disorders and/or mucositis/stomatitis and/or hepatic disorders and/or digestive symptoms and/or respiratory symptoms and/
or skin ulceration. 
T A B L E  2  (Continued)
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T A B L E  3  Factors associated to artificial nutrition use in the last 7 and 31 d before death: multivariate analysis (logistic regressions)
 
The last 7 d before death The last 31 d before death
N = 11 723 (2.9%)
P
N = 20 429 (5.1%)
PaOR (95% CI) aOR (95% CI)
Sex
Men (vs women) 1.11 (1.06-1.15) <.001 1.07 (1.03-1.10) <.001
Age at death (years)
≥80 (vs <80) 0.48 (0.45-0.50) <.001 0.48 (0.46-0.50) <.001
Year of death
2014 (vs 2013) 0.99 (0.94-1.04) .646 1.01 (0.97-1.05) .820
2015 (vs 2013) 0.91 (0.86-0.96) <.001 0.93 (0.89-0.97) <.001
2016 (vs 2013) 0.98 (0.93-1.03) .410 0.95 (0.91-0.99) .013
Hospitalization stay duration (days)
[8-31] (vs ≤7) 1.54 (1.45-1.64) <.001 1.84 (1.76-1.93) <.001
>31 (vs ≤7) 1.44 (1.38-1.49) <.001 1.73 (1.67-1.79) <.001
Hospital type
Speciality (vs non speciality) 1.53 (1.47-1.59) <.001 1.45 (1.41-1.50) <.001
Cancer localization
Digestivea (vs NDHANb) 1.18 (1.14-1.23) <.001 1.31 (1.27-1.35) <.001
Head and neck (vs NDHANb) 2.24 (2.09-2.40) <.001 2.71 (2.57-2.85) <.001
Metastasis
Presence (vs no) 0.76 (0.73-0.79) <.001 0.79 (0.77-0.82) <.001
Comorbidities (Charlson)c
1 or 2 (vs absence) 1.27 (1.21-1.32) <.001 1.12 (1.16-1.24) <.001
3 or 4 (vs absence) 1.26 (1.19-1.33) <.001 1.19 (1.14-1.24) <.001
≥5 (vs absence) 1.30 (1.21-1.39) <.001 1.24 (1.18-1.31) <.001
Malnutrition
Mild (vs absence) 2.53 (2.23-2.88) <.001 2.47 (2.25-2.71) <.001
Moderate (vs absence) 1.58 (1.49-1.68) <.001 1.74 (1.67-1.82) <.001
Severe (vs absence) 1.77 (1.69-1.85) <.001 2.19 (2.12-2.27) <.001
Other casesd (vs absence) 1.82 (1.61-2.05) <.001 1.91 (1.75-2.09) <.001
Specific biologic/clinical situationse
Presence of at least 1f (vs no) 1.40 (1.34-1.46) <.001 1.53 (1.47-1.58) <.001
Dementia
Presence (vs no) 0.62 (0.54-0.71) <.001 0.62 (0.56-0.68) <.001
Chemotherapy useg
Yes (vs no) 1.05 (0.98-1.11) .148 1.14 (1.10-1.18) <.001
Palliative care useg
Yes (vs no) 0.39 (0.37-0.40) <.001 0.53 (0.51-0.54) <.001
Note: Bold values: P-values < .05.
Abbreviation: aOR (95% CI), adjusted odd ratio with the 95% confidence interval.
aDigestive cancers: oesophageal, pancreas, and other digestive localizations. 
bNDHAN: Non-digestive and non-head-and-neck cancers. 
cCharlson modified score (excluding malignancies/metastasis). 
dProtein energy malnutrition non-defined according to severity. 
eBiological and/or clinical situation(s) potentially source of prescription of artificial nutrition. 
fCachexia and/or anorexia and/or metabolic disorders and/or mucositis/stomatitis and/or hepatic disorders and/or digestive symptoms and/or respiratory symptoms and/
or skin ulceration. 
gThe last 7 or 31 d depending on the endpoint (last 7 or 31 d before death, respectively). 
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Despite these satisfactory findings, it is necessary to 
question the last remaining obstacles to the reduction in ar-
tificial nutrition use in the French context. Since the recent 
French law (2016), called the French Claeys-Leonetti Law 
(LOI n° 2016-87 du 2 février 2016 créant de nouveaux droits 
en faveur des malades et des personnes en fin de vie), the 
notion of “treatment” includes artificial nutrition that allows 
withdrawing it in limited life expectancy situations. Since 
artificial nutrition is a treatment, the initiation, termination, 
and withholding of it must be medically and/or ethically (and 
consequently legally) justified.12 Beyond medical, ethical 
or legislative factors, the thought processes that influence 
decision-making regarding the issues of implementation, 
maintaining, or withdrawing artificial nutrition30 should 
be explored. Strong opinions surrounding these decisions 
are rooted in beliefs, representations, and personal and cul-
tural experiences, referring to a basic physiological need 
associated with psychological, social, and symbolic signif-
icance.30-32 The perspectives of patients/families and pro-
fessionals provide the basis for decisions regarding artificial 
nutrition. First, the patients and families may believe that: 
(a) regarding maintaining/implementing artificial nutrition: 
it may help them to survive by preventing dehydration and 
increasing physical strength, it provides a primary neces-
sity33-35 required by all human beings, it is supported by their 
religion, and it is a symbol of their families' love33; (b) while 
withdrawing/stopping artificial nutrition may be related to an 
act leading to death30 and, may give the perception that the 
health care team is negligent.32 Second, professionals' beliefs 
may contribute to the decision about artificial nutrition at 
the end of life due to the significant influence they have on 
patients/families in the setting of a trusted caregiver relation-
ship. Physicians who do not frequently participate in the care 
of terminally ill patients are more likely to consider artificial 
nutrition as necessary,31 to consider the discontinuation as a 
form of intentional death-hastening,36 and worry about being 
accused of performing euthanasia if they stop artificial nu-
trition.37 The more-familiar professionals would argue that 
artificial nutrition only prolongs the dying process.12 Last, 
the meaning of continuing nutrition at the end-of-life differs 
according to cultural aspects. In western cultures, eating is 
associated with survival and lack of nutrition is related to 
death. Elsewhere, nobody dies hungry (Taiwanese belief)31 
or stops eating to prepare for a dignified death (Hindu tradi-
tion). The discrepancies between the different points of view 
(families/patients vs professionals) should be reduced.38 
Legal documentation, patients' written wishes, and expressed 
wishes to a (familial or professional) proxy may prevent dis-
agreements and misunderstandings and may facilitate the 
final decisions.32 Providers must encourage early open con-
versations with patients/families regarding the course of the 
disease and the approaching end of life, ensuring the respect 
of their preference regarding terminal care and the place of 
death.39 The professionals must provide education and guid-
ance about the risks and benefits involved in artificial nutri-
tion and communicate clearly about the limited evidence of 
its beneficial effects. This communication involves ethical 
challenges that have been widely debated in the last decades.
4.1 | Some limitations should be discussed
The generalizability of our results should be discussed. Only 
patients who died in hospitals were studied, and future stud-
ies may explore the phenomenon in other conditions of death, 
such as patients whose care was managed in rehabilitation 
centers and at home.
The retrospective design prevented us from truly explor-
ing the relations between the time of the decision to pursue 
artificial nutrition or not and to implement artificial nutrition 
or not and the expected prognosis of the patient. Indeed, the 
4 last weeks that were considered in the study were prob-
ably not the 4 last weeks expected by the physicians at the 
present time. The trajectory of cancer patients is not easily 
predictable, even in the last days. Physicians have been found 
to be overoptimistic regarding the prognosis of terminally ill 
patients.40 The maintenance of artificial nutrition may be due 
to an overestimation of the prognosis. However, surprisingly, 
similar results were found between the analysis of the last 
7 days and the last 31 days. A prospective design would more 
appropriate to link the decision to stop/maintain artificial nu-
trition with the expected time until death.
The accuracy of the findings, due to the source of the data 
(an administrative registry), depends on the coding rules and 
the skills of the encoders.41 These databases were originally 
designed for the optimization of funding allocation of the 
French health facilities. We may hypothesize that the coding 
procedures might be slightly guided by this first objective, 
leading to misestimations. The absence of artificial hydra-
tion, not catched by the French classification of medical acts, 
might underestimate the global prevalence of “artificial nutri-
tion and hydration.” Future studies, based on other sources of 
data, should be used to confirm some assertions.
The expectations of prescribers and patients/families 
should be investigated as key items to assess the quality 
and adequacy of artificial nutrition at the end of life. Future 
studies should further explore these aspects using mixed ap-
proaches (quali-quantitative studies).
5 |  CONCLUSION
This study indicates that the use of artificial nutrition near 
the end of life is rather low, which is in keeping with cur-
rent clinical guidelines. The identification of factors asso-
ciated with the use of artificial nutrition, such as cancer 
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localization, presence of comorbidities or specific symp-
toms, may help to better manage its use, and may improve 
communication with patients, families, professionals, and 
health policy makers.
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